Stay updated with breaking news from Sclerosis Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A second patient also showed clinical improvements in the Positron Emission Tomography (PET) imaging analysis, neurologic exam, and in the Timed 25-Foot Walk test, following three months of treatment.
This Intermediate-Size Patient Population Expanded Access program will follow the same clinical dosing regimen as the two ongoing single-patient expanded access programs in SPMS patients.Tiziana
This clinical trial, the first-ever oral immunotherapy for patients with mild-to-moderately active Crohn's Disease, is anticipated to be completed by Q4, 2022. NEW YORK, March 25, 2022) ("Tiziana"
This clinical trial, the first-ever oral immunotherapy for patients with mild-to-moderately active Crohn's Disease, is anticipated to be completed by Q4, 2022.
Tiziana Announces Initiation of Phase 1b Clinical Trial in Crohn's Disease Patients to Evaluate Oral Capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody ... | March 25, 2022